Olivier Harismendy

22.4k total citations · 1 hit paper
90 papers, 4.9k citations indexed

About

Olivier Harismendy is a scholar working on Molecular Biology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Olivier Harismendy has authored 90 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Molecular Biology, 33 papers in Cancer Research and 17 papers in Pathology and Forensic Medicine. Recurrent topics in Olivier Harismendy's work include Cancer Genomics and Diagnostics (20 papers), RNA modifications and cancer (10 papers) and RNA Research and Splicing (10 papers). Olivier Harismendy is often cited by papers focused on Cancer Genomics and Diagnostics (20 papers), RNA modifications and cancer (10 papers) and RNA Research and Splicing (10 papers). Olivier Harismendy collaborates with scholars based in United States, France and Germany. Olivier Harismendy's co-authors include Kelly A. Frazer, Nathan E. Lewis, Adam Officer, Erick Armingol, Eric J. Topol, Nicholas J. Schork, Sarah S. Murray, Xiaoyun Wang, Shawn Yost and Xiaoyuan Song and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Olivier Harismendy

87 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Deciphering cell–cell interactions and communication from gene expression

2020 742 citations Adam Officer, Olivier Harismendy et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Olivier Harismendy United States	32	3.0k	1.0k	774	611	507	90	4.9k
Anna Asplund Sweden	32	3.7k 1.2×	983 1.0×	441 0.6×	723 1.2×	450 0.9×	71	5.3k
Jonghwan Kim United States	37	5.7k 1.9×	894 0.9×	780 1.0×	669 1.1×	623 1.2×	119	7.3k
Reiner Strick Germany	38	2.6k 0.9×	790 0.8×	572 0.7×	785 1.3×	760 1.5×	117	5.2k
Richard Bourgon United States	28	3.5k 1.2×	1.1k 1.1×	549 0.7×	1.4k 2.3×	862 1.7×	55	5.4k
Jüri Reimand Canada	26	4.3k 1.4×	1.4k 1.4×	818 1.1×	648 1.1×	634 1.3×	57	6.3k
Nan Hu China	40	2.8k 0.9×	825 0.8×	363 0.5×	595 1.0×	617 1.2×	199	6.1k
Mitchell Stark Australia	27	5.1k 1.7×	1.3k 1.3×	754 1.0×	1.2k 1.9×	716 1.4×	65	7.5k
Syed Haider United Kingdom	36	3.3k 1.1×	1.6k 1.5×	602 0.8×	1.0k 1.7×	506 1.0×	111	5.0k
Jeffrey Lee United States	28	4.0k 1.3×	627 0.6×	708 0.9×	973 1.6×	662 1.3×	84	6.1k

Countries citing papers authored by Olivier Harismendy

Since Specialization

Citations

This map shows the geographic impact of Olivier Harismendy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olivier Harismendy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olivier Harismendy more than expected).

Fields of papers citing papers by Olivier Harismendy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olivier Harismendy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olivier Harismendy. The network helps show where Olivier Harismendy may publish in the future.

Co-authorship network of co-authors of Olivier Harismendy

This figure shows the co-authorship network connecting the top 25 collaborators of Olivier Harismendy. A scholar is included among the top collaborators of Olivier Harismendy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olivier Harismendy. Olivier Harismendy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jameson, Nathan M., Catherine Lee, Xiao Guo, et al.. (2025). The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRAS G12C Inhibitors in Preclinical Models. Cancer Research Communications. 5(2). 240–252. 3 indexed citations

Ma, Jianhui, Arkene Levy, Zhen Cai, et al.. (2025). Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid Tumors. Molecular Cancer Therapeutics. 24(8). 1171–1185. 1 indexed citations

Allevato, Michael M., Keiichi Koshizuka, Daniela Nachmanson, et al.. (2024). A genome-wide CRISPR screen reveals that antagonism of glutamine metabolism sensitizes head and neck squamous cell carcinoma to ferroptotic cell death. Cancer Letters. 598. 217089–217089. 8 indexed citations

O’Keefe, Thomas J., Olivier Harismendy, & Anne M. Wallace. (2023). Bilateral mastectomy associated with higher breast cancer mortality among patients with estrogen receptor positive progesterone receptor negative localized breast cancer. Chinese Clinical Oncology. 12(1). 3–3. 2 indexed citations

Liu, Wen, Heekyung Chung, Hooman Izadi, et al.. (2023). Abstract 2153: Cyclin E1 protein overexpression sensitizes ovarian cancer cells to ZN-c3, a novel, selective and oral bioavailable inhibitor of Wee1. Cancer Research. 83(7_Supplement). 2153–2153. 3 indexed citations

Papadas, Athanasios, Gauri Deb, Adam Officer, et al.. (2022). Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment. Cell Reports. 40(7). 111201–111201. 21 indexed citations

O’Keefe, Thomas J., Olivier Harismendy, & Anne M. Wallace. (2022). Histopathological growth distribution of ductal carcinoma in situ: tumor size is not “one size fits all”. Gland Surgery. 11(2). 307–318. 3 indexed citations

Makris, Eleftherios, Erik N. Bergstrom, Jorge de la Torre, et al.. (2021). Synchronous, Yet Genomically Distinct, GIST Offer New Insights Into Precise Targeting of Tumor Driver Mutations. JCO Precision Oncology. 5(5). 525–532. 1 indexed citations

Wu, Victoria H., Huwate Yeerna, Nijiro Nohata, et al.. (2019). Illuminating the Onco-GPCRome: Novel G protein–coupled receptor-driven oncocrine networks and targets for cancer immunotherapy. Journal of Biological Chemistry. 294(29). 11062–11086. 135 indexed citations

10.

Ghia, Emanuela M., Laura Z. Rassenti, Donna Neuberg, et al.. (2019). Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia. Blood. 133(25). 2651–2663. 16 indexed citations

11.

Day, Terry A., Keisuke Shirai, Paul E. O’Brien, et al.. (2018). Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial. Clinical Cancer Research. 25(4). 1156–1164. 67 indexed citations

12.

Sagredo, Eduardo A., Alejandro Blanco, Alfredo Sagredo, et al.. (2018). ADAR1-mediated RNA-editing of 3′UTRs in breast cancer. Biological Research. 51(1). 36–36. 39 indexed citations

13.

Carroll, Kate, Alex K. Bryant, Brian R. Hirshman, et al.. (2018). Interaction Between the Contributions of Tumor Location, Tumor Grade, and Patient Age to the Survival Benefit Associated with Gross Total Resection. World Neurosurgery. 111. e790–e798. 10 indexed citations

14.

Zhou, Yuanshuai, Fan Zhang, Hai Zhang, et al.. (2018). Nuclear respiratory factor 1 promotes spheroid survival and mesenchymal transition in mammary epithelial cells. Oncogene. 37(47). 6152–6165. 21 indexed citations

15.

Schwaederlé, Maria, Hatim Husain, Paul T. Fanta, et al.. (2016). Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clinical Cancer Research. 22(22). 5497–5505. 102 indexed citations

16.

Levy, Éric, Rachel Marty, Brian Woo, et al.. (2016). Immune DNA signature of T-cell infiltration in breast tumor exomes. Scientific Reports. 6(1). 30064–30064. 24 indexed citations

17.

Yost, Shawn, Sandra Pastorino, Sophie Rozenzhak, et al.. (2013). High-Resolution Mutational Profiling Suggests the Genetic Validity of Glioblastoma Patient-Derived Pre-Clinical Models. PLoS ONE. 8(2). e56185–e56185. 21 indexed citations

18.

Bao, Lirong, Minya Pu, Brian Crain, et al.. (2012). Abstract P2-06-01: Breast-to-breast metastasis can cause hormone-receptor positive/triple negative bilateral synchronous tumors. Cancer Research. 72(24_Supplement). P2–6. 1 indexed citations

19.

Bhatia, Gaurav, Vikas Bansal, Olivier Harismendy, et al.. (2010). A Covering Method for Detecting Genetic Associations between Rare Variants and Common Phenotypes. PLoS Computational Biology. 6(10). e1000954–e1000954. 71 indexed citations

20.

Bansal, Vikas, Olivier Harismendy, Ryan Tewhey, et al.. (2010). Accurate detection and genotyping of SNPs utilizing population sequencing data. Genome Research. 20(4). 537–545. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact